Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.

ABSTRACT:

Background

To determine if the intranasal delivery of neuroactive compounds is a viable, long-term treatment strategy for progressive, chronic neurodegenerative disorders, such as Parkinson's disease (PD), intranasal methodologies in preclinical models comparable to humans are needed.

New method

We developed a methodology to evaluate the repeated intranasal delivery of neuroactive compounds on the non-human primate (NHP) brain, without the need for sedation. We evaluated the effects of the neuroactive peptide, DNSP-11 following repeated intranasal delivery and dose-escalation over the course of 10-weeks in Rhesus macaques. This approach allowed us to examine striatal target engagement, safety and tolerability, and brain distribution following a single ¹²⁵I-labeled

SUBMITTER: Stenslik MJ 

PROVIDER: S-EPMC5965701 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature